Mild hyperhomocysteinemia, C677T polymorphism on methylenetetrahydrofolate reductase gene and the risk of macroangiopathy in type 2 diabetes: a prospective study

Hoogeveen EK, Kostense PJ, Beks PJ, Mackaay AJ, Jakobs C, Bouter LM et al (1998) Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus: a population-based study. Arterioscler Thromb Vasc Biol 18:133–138

Elias AN, Eng S (2005) Homocysteine concentrations in patients with diabetes mellitus—relationship to microvascular and macrovascular disease. Diabetes Obes Metab 7:117–121

Audelin MC, Genest J Jr (2001) Homocysteine and cardiovascular disease in diabetes mellitus. Atherosclerosis 159:497–511

Jacques PF, Bostom AG, Wilson PW, Rich S, Rosenberg IH, Selhub J (2001) Determinants of plasma total homocysteine concentration in the Frammingham Offspring Cohort. Am J Clin Nutr 73:613–621

Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG et al (1995) A candidate genetic risk factor for vascular disease: a common mutation at the methylenetetrahydrofolate reductase. Nat Genet 10:111–113

Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG, The MTHFR Studies Collaboration Group (2002) MTHFR 677 CT polymorphism and risk of coronary heart disease. JAMA 288:2023–2031

Russo GT, Di Benedetto A, Giorda C, Alessi E, Crisafulli G, Ientile R et al (2004) Correlates of total homocysteine plasma concentration in type 2 diabetes. Eur J Clin Invest 34:197–204

Passaro A, Calzoni F, Volpato S, Nora ED, Pareschi PL, Zamboni PF et al (2003) Effect of metabolic control on homocysteine levels in type 2 diabetic patients: a 3-year follow-up. J Intern Med 254:264–271

Hoogeven EK, Kostense PJ, Jakobs C (1997) Does metformin increase the serum total homocysteine level in NIDDM? J Int Med 242:389–394

Buysschaert M, Dramais AS, Wallemacq PE, Hermans MP (2000) Hyperhomocysteinemia in type 2 diabetes: relationship to macroangiopathy, nephropathy, and insulin resistance. Diabetes Care 23:1816–1822

The Expert Committee on the Diagnosis of Diabetes Mellitus (1997) Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 20:1183–1197

Giorda CB, Avogaro A, Maggini M, Lombardo F, Mannucci E, Turco S, Diabetes and Informatics Study Group (2008) Recurrence of cardiovascular events in patients with type 2 diabetes: epidemiology and risk factors. Diabetes Care 31:2154–2159

The DAI Study Group (2004) Prevalence of coronary heart disease in a cohort of type 2 diabetic patients in Italy: the DAI study. Diabet Med 21:738–745

Rose GA, Blackburn H (1968) Cardiovascular survey methods. Monogr Ser World Health Organ 56:1–188

Welch GN, Loscalzo J (1998) Homocysteine and atherothrombosis. N Engl J Med 338:1042–1050

Ueland PM, Refsum H, Beresford SA, Vollset SE (2000) The controversy over homocysteine and cardiovascular risk. Am J Clin Nutr 72:324–332

Araki A, Sako Y, Ito H (1993) Plasma homocysteine concentrations in Japanese patients with non insulin-dependent diabetes mellitus: effect of parenteral methylcobalamin treatment. Atherosclerosis 103:149–157

Chico A, Perez A, Cordoba A, Arcelus R, Carreras G, De Leiva A et al (1998) Plasma homocysteine is related to albumin excretion rate in patients with diabetes mellitus: a new link between diabetic nephropathy and cardiovascular disease? Diabetologia 41:684–693

Hoogeveen EK, Kostense PJ, Jakobs C, Dekker JM, Nijpels G, Heine RJ et al (2000) Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes: 5-year follow-up of the Hoorn study. Circulation 101:1506–1511

Soinio M, Marniemi J, Laakso M, Lehto S, Ronnemaa T (2004) Elevated plasma homocysteine level is an independent predictor of coronary heart disease events in patients with type 2 diabetes mellitus. Ann Intern Med 140:94–100

Ndrepepa G, Kastrati A, Braun S, Koch W, Kölling K, Mehilli J et al (2006) A prospective cohort study of predictive value of homocysteine in patients with type 2 diabetes and coronary artery disease. Clin Chim Acta 373:70–76

Selhub J (2006) The many facets of hyperhomocysteinemia: studies from the Framingham cohorts. J Nutr 136:1726S–1730S

Brattström L, Wilcken DEL (2000) Homocysteine and cardiovascular disease: cause or effect? Am J Clin Nutr 72:315–323

Passaro A, D’Elia K, Pareschi P, Calzoni F, Carantoni M, Fellin R et al (2000) Factors influencing plasma homocysteine levels in type 2 diabetes. Diabetes Care 23:420–421

Russo GT, Friso S, Jacques PF, Rogers G, Cucinotta D, Wilson PW et al (2003) Age and gender affect the relation between methylenetetrahydrofolate reductase C677T genotype and fasting plasma homocysteine concentrations in the Framingham Offspring Study cohort. J Nutr 133:3416–3421

Arai K, Yamasaki Y, Kaijmoto YY, Watada H, Umayahara Y, Kodama M et al (1997) Association of methylenetetrahydrofolate reductase gene polymorphism with carotid arterial wall thickening and myocardial infarction risk in NIDDM. Diabetes 46:2102–2104

Hasegawa G, Obayashi H, Kamiuchi K, Nakai M, Kanatsuna T, Yamaguchi M et al (2003) The association between end-stage diabetic nephropathy and methylenetetrahydrofolate reductase genotype with macroangiopathy in type2 diabetes mellitus. Exp Clin Endocrinol Diabetes 111:132–138

Sun J, Xu Y, Xue J, Zhu Y, Lu H (2005) Methylenetetrahydrofolate reductase polymorphism associated with susceptibility to coronary heart disease in Chinese type 2 diabetic patients. Mol Cell Endocrinol 229:95–101

Mazza A, Motti C, Nulli A, Pastore A, Andreotti F, Ammaturo V et al (1999) Serum homocysteine, MTHFR gene polymorphism, and carotid intimal-medial thickness in NIDDM subjects. J Thromb Thrombolysis 8:207–212

Scaglione L, Gambino R, Rolfo E, Lillaz E, Gai M, Cassader M et al (2002) Plasma homocysteine, methylenetetrahydrofolate reductase gene polymorphism and carotid intima-media thickness in Italian type 2 diabetic patients. Eur J Clin Invest 32:24–28

The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators (2006) Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 354:1567–1577

B-Vitamin Treatment Trialists’ Collaboration (2006) Homocysteine-lowering trials for prevention of cardiovascular events: a review of the design and power of the large randomized trials. Am Heart J 151:282–287

Avogaro A, Giorda C, Maggini M, Mannucci E, Raschetti R, Raschetti R, Raschetti R, Raschetti R, Lombardo F, Diabetes, Informatics Study Group, Association of Clinical Diabetologists, Istituto Superiore di Sanità (2007) Incidence of coronary heart disease in type 2 diabetic men and women: impact of microvascular complications, treatment, and geographic location. Diabetes Care 30:1241–1247

Cheng TY, Wen SF, Astor BC, Tao XG, Samet JM, Wen CP (2008) Mortality risks for all causes and cardiovascular diseases and reduced GFR in a middle-aged working population in Taiwan. Am J Kidney Dis 52:1051–1060